Showing results (131-140 of 331) with videos related to
Sort By:
Pageof 34
Journal for Immunotherapy of Cancer|May 17, 2020
Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitisMeghan J Mooradian, Daniel Y Wang, Alexandra Coromilas, et al.The Oncologist|May 13, 2015
Clinical Activity of Ipilimumab in Acral Melanoma: A Retrospective ReviewDouglas B Johnson, Chengwei Peng, Richard G Abramson, et al.Annual Review of Pharmacology and Toxicology|September 2, 2020
Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang BalanceArthur Geraud, Paul Gougis, Aurore Vozy, et al.American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|September 25, 2019
Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?Mina F Nordness, Stephanie Hamel, Caroline M Godfrey, et al.Cancer Immunology Research|February 5, 2015
Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral CenterDouglas B Johnson, Debra L Friedman, Elizabeth Berry, et al.Journal of Surgical Oncology|July 3, 2019
Correlates of response and outcomes with talimogene laherperpvecAlice Y Zhou, Daniel Y Wang, Svetlana McKee, et al.Molecular Cancer Research : MCR|June 13, 2019
Identification of Targetable Recurrent MAP3K8 Rearrangements in Melanomas Lacking Known Driver MutationsBrian D Lehmann, Timothy M Shaver, Douglas B Johnson, et al.Oncogenesis|May 7, 2020
Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1RSuresh Bugide, Keshab Raj Parajuli, Suresh Chava, et al.Oncoimmunology|April 18, 2025
Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockadeNina B Curkovic, Rebecca Irlmeier, Xue Bai, et al.Journal for Immunotherapy of Cancer|May 24, 2019
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance studyDouglas B Johnson, Ali Manouchehri, Alexandra M Haugh, et al.Pageof 34